ISU Abxis Co., Ltd.
ISU Abxis Co., Ltd., a prominent player in the biotechnology sector, is headquartered in South Korea (KR) and operates extensively across Asia and beyond. Founded in 2004, the company has established itself as a leader in the development of innovative diagnostic solutions and therapeutic antibodies, catering to the growing demands of the healthcare industry. ISU Abxis is renowned for its cutting-edge products, including monoclonal antibodies and diagnostic kits, which are distinguished by their high specificity and reliability. The company’s commitment to research and development has led to significant advancements in immunology and molecular diagnostics, positioning it as a trusted partner in the global market. With a focus on quality and innovation, ISU Abxis continues to achieve notable milestones, solidifying its reputation as a key contributor to the biotechnology landscape.
DitchCarbon Score
How does ISU Abxis Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
ISU Abxis Co., Ltd.'s score of 20 is lower than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
ISU Abxis Co., Ltd.'s reported carbon emissions
ISU Abxis Co., Ltd., headquartered in South Korea (KR), currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. As a result, ISU Abxis appears to lack formal commitments to carbon reduction initiatives or industry-standard climate frameworks such as the Science Based Targets initiative (SBTi). Without emissions data or reduction strategies, it is unclear how the company is addressing climate change or its carbon footprint within the biopharmaceutical sector. In the context of the industry, many companies are increasingly adopting ambitious climate commitments and reporting frameworks to enhance transparency and accountability regarding their environmental impact. However, ISU Abxis has yet to establish a public stance or measurable goals in this area.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
ISU Abxis Co., Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
